<DOC>
	<DOCNO>NCT00254410</DOCNO>
	<brief_summary>The goal clinical research study learn use combination fludarabine , cyclophosphamide , mitoxantrone plus rituximab , growth factor pegylated filgrastim , improve response treatment , increase time response last , patient previously untreated CLL . The safety combination also study .</brief_summary>
	<brief_title>FCM-R ( Fludarabine , Cyclophosphamide , Mitoxantrone , Rituximab ) Previously Untreated Patients With Chronic Lymphocytic Leukemia ( CLL ) &lt; 70 Years</brief_title>
	<detailed_description>Fludarabine , cyclophosphamide , mitoxantrone chemotherapy drug use treatment CLL . Rituximab monoclonal antibody bind CLL cell cause cell death . Pegfilgrastim ( Neulasta ) growth factor help bone marrow produce white cell ( neutrophil ) approve drug treat suppression marrow function cause chemotherapy . If eligible take part study , begin treatment . Rituximab give needle vein ( IV ) Day 1 Courses 1-6 . The first infusion may take 8 hour . For every dose rituximab , infusion may take 2-4 hour . The length infusion time depend whether reaction infusion . The dose level rituximab may increase Cycles 2-6 well . The drug acetaminophen ( Tylenol ) diphenhydramine hydrochloride ( Benadryl ) give dose rituximab . This do decrease risk side effect . If side effect occur rituximab treatment , drug may stop side effect go away restart , time outpatient area may longer occurs . One day first dose rituximab ( Day 2 ) , fludarabine cyclophosphamide give IV every day 3 day ( Days 2 , 3 , 4 ) , mitoxantrone give IV Day 2 . Fludarabine cyclophosphamide give 30-minute infusion , infusion mitoxantrone take 30-60 minute . After first treatment cycle , drug give Days 1 , 2 , 3 every cycle . Pegfilgrastim give subcutaneous injection ( injection skin ) per treatment cycle , right receive last chemotherapy drug ( word , Day 4 first cycle , Day 3 every cycle ) . Other IV fluid , saline , give treatment day keep hydrate , mean clinic visit take 6 hour . The combination repeat every 4 6 week total 6 course . The first treatment give UTMDACC outpatient clinic . The 5 course perform either UTMDACC home regular physician . During treatment cycle , blood sample ( 1 teaspoon ) drawn every 1-2 week . Bone marrow biopsy perform end Cycles 3 6 chemotherapy . With exception rituximab , dose drug use throughout study unless side effect become severe . In case , dose may lower treatment may stop . You take study disease get bad . After Course 6 chemotherapy finish , blood test ( 2 teaspoon ) perform every 6-12 month . This investigational study . The FDA approve drug use study , commercially available . However , use study combination consider investigational . Up 30 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Untreated CLL , CLL/PLL , SLL ( small lymphocytic lymphoma ) indication therapy ( Indications therapy include least one following : ) one diseaserelated symptom [ fever , night sweat , weight loss , pronounce fatigue ] ; ii ) advance stage disease ( Rai stage &gt; /= 3 Binet stage C ) ; iii ) autoimmune anemia and/or thrombocytopenia unresponsive therapy ; iv ) massive progressive hepatomegaly and/or splenomegaly and/or lymphadenopathy ; iv ) recurrent infection ; v ) rapid lymphocyte double time &lt; 6 month ) . 2 . Age &lt; 70 year . 3 . Adequate liver function ( total bilirubin &lt; /= 2.5 mg/dL , SGPT &lt; /=4 x ULN ) renal function ( serum creatinine &lt; /= 2.0 mg/dL ) . Patients renal liver dysfunction due suspect organ infiltration lymphocyte may eligible discussion Principal Investigator , upper limit creatinine even circumstance must creatinine &lt; 3mg/dL bilirubin &lt; 6 mg/dL . Patients Gilbert 's syndrome may enter study bilirubin level &lt; /= 4 mg/dL . 4 . Beta2microglobulin &lt; /= 4 mg/dL . 5 . ECOG performance status &lt; /= 2 . 6 . Signed informed consent keep policy hospital . 7 . Male female patient fertile agree use effective barrier method birth control ( ie , latex condom , diaphragm , cervical cap , etc ) avoid pregnancy . Female patient childbearing potential ( nonchildbearing define &gt; /= 1 year postmenopausal surgically sterilize ) need negative serum urine pregnancy test within 14 day study enrollment . 1 . Active hepatitis B ( least one follow marker positive : HBsAg , HBeAg , IgM antiHBc , HBV DNA ) . 2 . Concurrent chemotherapy immunotherapy . 3 . Pregnant patient . 4 . History HIV 5 . Symptomatic CNS disease 6 . Symptomatic heart disease ( NYHA class &gt; /= 3 ) LV ejection fraction &lt; 40 % ( MUGA echocardiogram )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Untreated</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludara</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Mitoxantrone</keyword>
	<keyword>Novantrone</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>Pegylated Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>